Literature DB >> 11006373

Moving beyond fluorouracil for colorectal cancer.

R J Mayer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006373     DOI: 10.1056/NEJM200009283431309

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Hyperammonemic encephalopathy associated with 5-fluorouracil in a patient with previous orthotopic liver transplantation.

Authors:  Hemnishil K Marella; Rahul Peravali; Amit L Jain; Satheesh Nair; Benedict Maliakkal; Uchenna Agbim; Rajanshu Verma
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-01-09

2.  Evaluation of the 5-fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy.

Authors:  Yu Abe; Naoki Sakuyama; Tsuyoshi Sato; Kenji Kishine; Kiichi Nagayasu; Akinori Nakatani; Masayuki Kitajima; Tomoo Watanabe; Kazuhiko Nishimura; Takumi Ochiai; Isao Nagaoka
Journal:  Mol Clin Oncol       Date:  2019-07-03

3.  Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines.

Authors:  Ivana Grivicich; Andréa Regner; Caroline Zanoni; Larissa Procópio Correa; Geraldo Pereira Jotz; João Antônio Pêgas Henriques; Gilberto Schwartsmann; Adriana Brondani da Rocha
Journal:  Int J Colorectal Dis       Date:  2007-03-28       Impact factor: 2.571

4.  Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy.

Authors:  Hee Jung Yi; Kyung Sook Hong; Nara Moon; Soon Sup Chung; Ryung-Ah Lee; Kwang Ho Kim
Journal:  Ann Surg Treat Res       Date:  2016-02-26       Impact factor: 1.859

5.  Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.

Authors:  Kohei Shigeta; Yoshiyuki Ishii; Hirotoshi Hasegawa; Koji Okabayashi; Yuko Kitagawa
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

Review 6.  Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.

Authors:  Cathy Eng
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

Review 7.  Treatment of colorectal liver metastases.

Authors:  Nabil Ismaili
Journal:  World J Surg Oncol       Date:  2011-11-24       Impact factor: 2.754

8.  Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer.

Authors:  Valiollah Mehrzad; Mahnaz Roayaei; Mohammad Saleh Peikar; Elham Nouranian; Fariborz Mokarian; Mohsen Khani; Somaieh Farzannia
Journal:  Adv Biomed Res       Date:  2016-01-29

9.  Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis.

Authors:  Jia Che; Lun Pan; Xiangling Yang; Zhiting Liu; Lanlan Huang; Chuangyu Wen; Aihua Lin; Huanliang Liu
Journal:  Mol Clin Oncol       Date:  2017-10-03

10.  Impact of multicellular tumor spheroids as an in vivo‑like tumor model on anticancer drug response.

Authors:  Bianca Galateanu; Ariana Hudita; Carolina Negrei; Rodica-Mariana Ion; Marieta Costache; Miriana Stan; Dragana Nikitovic; A Wallace Hayes; Demetrios A Spandidos; Aristidis M Tsatsakis; Octav Ginghina
Journal:  Int J Oncol       Date:  2016-04-01       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.